Tempus AI Stock Surges 30% as Morgan Stanley Boosts Revenue Outlook

Key Facts

1Tempus AI shares rallied nearly 29% this week following a positive report from Morgan Stanley.

2Morgan Stanley highlighted reimbursement-driven revenue lifts for the AI-powered diagnostics company.

Amid the rapid integration of artificial intelligence into healthcare diagnostics, Tempus AI shares experienced a significant breakout. According to reports, the stock rallied nearly 29% this week following an optimistic report from Morgan Stanley analysts on September 15. The surge was primarily triggered by the bank's focus on fresh reimbursement-driven revenue growth for the company's AI-powered diagnostic services, signaling a fundamental shift in its financial trajectory.

This rally is supported by strong quarterly performance, with Q2 2026 revenue reaching $382.49 million, a 21.6% increase year-over-year. Consequently, the company raised its full-year revenue guidance to a range of $1.595 billion to $1.605 billion. Per market data, this institutional optimism comes as Morgan Stanley (MS) closed at $202.51 on September 16, 2026, while peer financial institutions like Goldman Sachs (GS) and JPMorgan (JPM) stood at $937.98 and $348.92 respectively as of the same close.

At the close of September 16, 2026, TEM was priced at $69.97, having reached a day high of $71.48. Investors are now watching for the company to over-deliver on its 25% multiyear growth target as forward EPS estimates for 2027 show signs of improvement. With no major upcoming catalysts in the economic calendar for the next week, market participants will likely focus on whether the stock can maintain its position above recent support levels established during this breakout.